Blood Pressure Management for Kidney and Thyroid Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if more intensive blood pressure management can benefit patients with kidney or thyroid cancer, particularly when the cancer has metastasized and they are beginning a specific cancer treatment. The goal is to lower blood pressure to less than 120 mmHg and compare it to the usual target of less than 140 mmHg. The study includes two groups: one with regular blood pressure management and another with the intensive approach. It suits individuals with kidney or thyroid cancer who are undergoing certain treatments and have high blood pressure (130 mmHg or more). Participants must be willing to monitor their blood pressure at home and have internet access. As an unphased trial, this study provides a unique opportunity to contribute to understanding the benefits of intensive blood pressure management for cancer patients.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it mentions that if you are on medications that might interact with the trial's blood pressure medications, alternative options can be considered. It's best to discuss your specific medications with the trial team.
What prior data suggests that intensive blood pressure management is safe for patients with metastatic kidney or thyroid cancer?
Research has shown that carefully managing blood pressure can be safe for patients, including those with cancer. Studies have found that controlling blood pressure can lower the risk of heart problems without causing kidney issues. Specifically, one study found that it reduced heart risks in cancer survivors, suggesting this approach might be well-tolerated.
Additionally, another study found that early increases in blood pressure during cancer treatment with certain drugs were not linked to major heart problems. This suggests that careful blood pressure management might not cause serious issues for patients starting cancer therapy. Overall, current research supports that careful blood pressure management can be safe and helpful for patients, including those receiving cancer treatments.12345Why are researchers excited about this trial?
Researchers are excited about the intensive blood pressure management approach for kidney and thyroid cancer patients because it could offer a more precise way to control blood pressure. Unlike standard methods that follow a routine medication schedule, this approach intensively adjusts medication every two weeks until systolic blood pressure drops below 120 mmHg. This method involves frequent home monitoring, allowing for real-time adjustments and potentially leading to better blood pressure control. By tailoring the treatment to individual needs, researchers hope this strategy will improve patient outcomes and provide insights into managing blood pressure more effectively for those with cancer.
What evidence suggests that intensive blood pressure management is effective for metastatic kidney or thyroid cancer patients?
This trial will compare two approaches to blood pressure management for patients with kidney or thyroid cancer. Participants in Arm A will receive intensive systolic blood pressure management, targeting below 120 mmHg. Research has shown that closely managing blood pressure can significantly lower systolic blood pressure. Studies have found that controlling blood pressure reduces the risk of serious heart issues in cancer patients. For those with kidney or thyroid cancer, careful blood pressure management may also mitigate the side effects of certain cancer drugs, which can cause blood pressure to rise. Keeping it low might improve overall treatment outcomes. Participants in Arm B will receive usual blood pressure management, with a target of 140 mmHg. Early research suggests that aiming for a systolic blood pressure below 120 mmHg is safe and more beneficial than the usual target of 140 mmHg.12346
Who Is on the Research Team?
Bonnie Ky
Principal Investigator
ECOG-ACRIN Cancer Research Group
Are You a Good Fit for This Trial?
This trial is for adults with metastatic kidney or thyroid cancer who are starting anti-angiogenic tyrosine kinase inhibitor therapy. They must have cardiovascular disease or risk, chronic kidney disease with specific blood filtration rates, and controlled hepatitis if present. Participants need to be able to monitor their blood pressure at home, use contraception if necessary, and have internet access.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either intensive or standard systolic blood pressure management for 6 months. Intensive management involves increased medication every 2 weeks if SBP is 120 mmHg or higher, with home monitoring and data uploads.
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessment of symptoms, quality of life, and satisfaction with blood pressure care.
What Are the Treatments Tested in This Trial?
Interventions
- Intensive Blood Pressure Management
Find a Clinic Near You
Who Is Running the Clinical Trial?
ECOG-ACRIN Cancer Research Group
Lead Sponsor
National Cancer Institute (NCI)
Collaborator